Multi-OMIC profiling of survival and metabolic signaling networks in cells subjected to photodynamic therapy

Cellular and Molecular Life Sciences

Volumn 74, Issue 6, 2017, Pages 1133-1151

  Weijer, Ruud ^a   Clavier, Séverine ^b   Zaal, Esther A ^b   Pijls, Maud M E ^a   van Kooten, Robert T ^a   Vermaas, Klaas ^b   Leen, René ^a   Jongejan, Aldo ^a   Moerland, Perry D ^a   van Kampen, Antoine H C ^a   van Kuilenburg, André B P ^a   Berkers, Celia R ^b   Lemeer, Simone ^b   Heger, Michal ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Cancer therapy; Metallated phthalocyanines; Non resectable perihilar cholangiocarcinoma; Reactive oxygen species; Therapeutic recalcitrance; Tumor targeting

Indexed keywords

CELL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; HEAT SHOCK FACTOR; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; PHOTOSENSITIZING AGENT;

ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DETOXIFICATION; DOWN REGULATION; ENERGY METABOLISM; HUMAN; HUMAN CELL; MACROPHAGE; MOLECULAR BIOLOGY; MOLECULAR DYNAMICS; MULTI OMIC ANALYSIS; PERIHILAR CHOLANGIOCARCINOMA CELL; PHOTODYNAMIC THERAPY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVAL RATE; VASCULAR ENDOTHELIAL CELL; ANIMAL; CELL DEATH; CELL LINE; DRUG EFFECTS; GENETIC TRANSCRIPTION; METABOLISM; METABOLOME; METABOLOMICS; MOUSE; OXIDATION REDUCTION REACTION; PHOTOCHEMOTHERAPY; PROCEDURES; PROTEOMICS; TIME FACTOR; UPREGULATION;

ANIMALS; CELL DEATH; CELL LINE; CELL SURVIVAL; DOWN-REGULATION; ENERGY METABOLISM; HUMANS; METABOLIC NETWORKS AND PATHWAYS; METABOLOME; METABOLOMICS; MICE; OXIDATION-REDUCTION; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROTEOMICS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 84994119304     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-016-2401-0     Document Type: Article

References (80)

1. Plaetzer K, Krammer B, Berlanda J, Berr F, Kiesslich T (2009) Photophysics and photochemistry of photodynamic therapy: fundamental aspects. Lasers Med Sci 24(2):259–268. doi:10.1007/s10103-008-0539-1
2. Weijer R, Broekgaarden M, Kos M, van Vught R, Rauws EAJ, Breukink E, van Gulik TM, Storm G, Heger M (2015) Enhancing photodynamic therapy of refractory solid cancers: Combining second-generation photosensitizers with multi-targeted liposomal delivery. J Photochem Photobiol C Photochem Rev 23:103–131. doi:10.1016/j.jphotochemrev.2015.05.002
3. Sibille A, Lambert R, Souquet JC, Sabben G, Descos F (1995) Long-term survival after photodynamic therapy for esophageal cancer. Gastroenterology 108(2):337–344
4. Zeitouni NC, Shieh S, Oseroff AR (2001) Laser and photodynamic therapy in the management of cutaneous malignancies. Clin Dermatol 19(3):328–338
5. Sun ZQ (1992) Photodynamic therapy of nasopharyngeal carcinoma by argon or dye laser—an analysis of 137 cases. Zhonghua Zhong Liu Za Zhi 14(4):290–292
6. Benson RC Jr (1986) Laser photodynamic therapy for bladder cancer. Mayo Clin Proc 61(11):859–864
7. Nseyo UO, Dougherty TJ, Boyle DG, Potter WR, Wolf R, Huben R, Pontes JE (1985) Whole bladder photodynamic therapy for transitional cell carcinoma of bladder. Urology 26(3):274–280
8. Quyn AJ, Ziyaie D, Polignano FM, Tait IS (2009) Photodynamic therapy is associated with an improvement in survival in patients with irresectable hilar cholangiocarcinoma. HPB (Oxford) 11(7):570–577. doi:10.1111/j.1477-2574.2009.00102.x
9. Broekgaarden M, Weijer R, van Gulik TM, Hamblin MR, Heger M (2015) Tumor cell survival pathways activated by photodynamic therapy: a molecular framework for inhibition strategies. Cancer Metastasis Rev:1–48
10. Broekgaarden M, van Vught R, Oliveira S, Roovers RC, van Bergen en Henegouwen PM, Pieters RJ, van Gulik TM, Breukink E, Heger M (2016) Site-specific conjugation of single domain antibodies to liposomes enhances photosensitizer uptake and photodynamic therapy efficacy. Nanoscale 8(12):6490–6494
11. Weijer R, Broekgaarden M, Krekorian M, Alles LK, van Wijk AC, Mackaaij C, Verheij J, van der Wal AC, van Gulik TM, Storm G, Heger M (2016) Inhibition of hypoxia inducible factor 1 and topoisomerase with acriflavine sensitizes perihilar cholangiocarcinomas to photodynamic therapy. Oncotarget 7(3):3341–3356. doi:10.18632/oncotarget.6490
12. Broekgaarden M, Weijer R, van Wijk AC, Cox RC, Egmond MR, Hoebe R, van Gulik TM, Heger M (2016) Photodynamic therapy with liposomal zinc phthalocyanine and tirapazamine increases tumor cell death via DNA damage. J Biomed Nanotechnol 12:1–16
13. Broekgaarden M, Weijer R, Krekorian M, van den IJssel B, Kos M, Alles LK, van Wijk AC, Bikadi Z, Hazai E, van Gulik TM, Heger M (2016) Inhibition of hypoxia-inducible factor 1 with acriflavine sensitizes hypoxic tumor cells to photodynamic therapy with zinc phthalocyanine-encapsulating cationic liposomes. Nano Res 9(6):1639–1662
14. Broekgaarden M, de Kroon AI, Gulik TM, Heger M (2014) Development and in vitro proof-of-concept of interstitially targeted zinc- phthalocyanine liposomes for photodynamic therapy. Curr Med Chem 21(3):377–391
15. Lee K, Zhang H, Qian DZ, Rey S, Liu JO, Semenza GL (2009) Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc Natl Acad Sci U S A 106(42):17910–17915. doi:10.1073/pnas.0909353106
16. Weijer R, Broekgaarden M, van Golen RF, Bulle E, Nieuwenhuis E, Jongejan A, Moerland PD, van Kampen AH, van Gulik TM, Heger M (2015) Low-power photodynamic therapy induces survival signaling in perihilar cholangiocarcinoma cells. BMC Cancer 15(1):1014. doi:10.1186/s12885-015-1994-2
17. Alexandratou E, Yova D, Loukas S (2005) A confocal microscopy study of the very early cellular response to oxidative stress induced by zinc phthalocyanine sensitization. Free Radic Biol Med 39(9):1119–1127. doi:10.1016/j.freeradbiomed.2005.06.006
18. Fabris C, Valduga G, Miotto G, Borsetto L, Jori G, Garbisa S, Reddi E (2001) Photosensitization with zinc (II) phthalocyanine as a switch in the decision between apoptosis and necrosis. Cancer Res 61(20):7495–7500
19. Herbst RS, Shin DM (2002) Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 94(5):1593–1611
20. Harder J, Waiz O, Otto F, Geissler M, Olschewski M, Weinhold B, Blum HE, Schmitt-Graeff A, Opitz OG (2009) EGFR and HER2 expression in advanced biliary tract cancer. World J Gastroenterol 15(36):4511–4517
21. Yang X, Wang W, Wang C, Wang L, Yang M, Qi M, Su H, Sun X, Liu Z, Zhang J, Qin X, Han B (2014) Characterization of EGFR family gene aberrations in cholangiocarcinoma. Oncol Rep 32(2):700–708. doi:10.3892/or.2014.3261
22. Joseph SO, Wu J, Muggia FM (2012) Targeted therapy: its status and promise in selected solid tumors. Part II: Impact on selected tumor subsets, and areas of evolving integration. Oncology (Williston Park) 26 (11):1021–1030, 1035
23. Postiglione I, Chiaviello A, Palumbo G (2011) Enhancing photodynamic therapy efficacy by combination therapy: dated, current and oncoming strategies. Cancers (Basel) 3(2):2597–2629
24. Shim CS, Cheon YK, Cha SW, Bhandari S, Moon JH, Cho YD, Kim YS, Lee LS, Lee MS, Kim BS (2005) Prospective study of the effectiveness of percutaneous transhepatic photodynamic therapy for advanced bile duct cancer and the role of intraductal ultrasonography in response assessment. Endoscopy 37(5):425–433. doi:10.1055/s-2005-861294
25. Post IC, de Boon WM, Heger M, van Wijk AC, Kroon J, van Buul JD, van Gulik TM (2013) Endothelial cell preservation at hypothermic to normothermic conditions using clinical and experimental organ preservation solutions. Exp Cell Res 319(17):2501–2513. doi:10.1016/j.yexcr.2013.05.011
26. Vichai V, Kirtikara K (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1(3):1112–1116. doi:10.1038/nprot.2006.179
27. Wu D, Lim E, Vaillant F, Asselin-Labat ML, Visvader JE, Smyth GK (2010) ROAST: rotation gene set tests for complex microarray experiments. Bioinformatics 26(17):2176–2182. doi:10.1093/bioinformatics/btq401
28. Ruijter JM, Ramakers C, Hoogaars WM, Karlen Y, Bakker O, van den Hoff MJ, Moorman AF (2009) Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data. Nucleic Acids Res 37(6):e45. doi:10.1093/nar/gkp045
29. Zhou H, Ye M, Dong J, Corradini E, Cristobal A, Heck AJ, Zou H, Mohammed S (2013) Robust phosphoproteome enrichment using monodisperse microsphere-based immobilized titanium (IV) ion affinity chromatography. Nat Protoc 8(3):461–480. doi:10.1038/nprot.2013.010
30. Cox J, Mann M (2008) MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 26(12):1367–1372. doi:10.1038/nbt.1511
31. Cox J, Neuhauser N, Michalski A, Scheltema RA, Olsen JV, Mann M (2011) Andromeda: a peptide search engine integrated into the MaxQuant environment. J Proteome Res 10(4):1794–1805. doi:10.1021/pr101065j
32. Raaijmakers LM, Giansanti P, Possik PA, Mueller J, Peeper DS, Heck AJ, Altelaar AF (2015) PhosphoPath: Visualization of phosphosite-centric dynamics in temporal molecular networks. J Proteome Res 14(10):4332–4341. doi:10.1021/acs.jproteome.5b00529
33. Berridge MV, Herst PM, Tan AS (2005) Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnol Annu Rev 11:127–152. doi:10.1016/s1387-2656(05)11004-7
34. Kutmon M, Riutta A, Nunes N, Hanspers K, Willighagen EL, Bohler A, Melius J, Waagmeester A, Sinha SR, Miller R, Coort SL, Cirillo E, Smeets B, Evelo CT, Pico AR (2016) WikiPathways: capturing the full diversity of pathway knowledge. Nucleic Acids Res 44(D1):D488–D494. doi:10.1093/nar/gkv1024
35. Broekgaarden M, Kos M, Jurg FA, van Beek AA, van Gulik TM, Heger M (2015) Inhibition of NF-kappaB in tumor cells exacerbates immune cell activation following photodynamic therapy. Int J Mol Sci 16(8):19960–19977. doi:10.3390/ijms160819960
36. Karin M, Cao Y, Greten FR, Li ZW (2002) NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2(4):301–310. doi:10.1038/nrc780
37. Iurlaro R, Munoz-Pinedo C (2015) Cell death induced by endoplasmic reticulum stress. The FEBS journal. doi:10.1111/febs.13598
38. Fujimoto M, Nakai A (2010) The heat shock factor family and adaptation to proteotoxic stress. The FEBS journal 277(20):4112–4125
39. Lee HJ, Kim JM, Kim KH, Heo JI, Kwak SJ, Han JA (2015) Genotoxic stress/p53-induced DNAJB9 inhibits the pro-apoptotic function of p53. Cell Death Differ 22(1):86–95. doi:10.1038/cdd.2014.116
40. Nishitoh H, Saitoh M, Mochida Y, Takeda K, Nakano H, Rothe M, Miyazono K, Ichijo H (1998) ASK1 is essential for JNK/SAPK activation by TRAF2. Mol Cell 2(3):389–395. doi:10.1016/S1097-2765(00)80283-X
41. Brand TM, Iida M, Li C, Wheeler DL (2011) The nuclear epidermal growth factor receptor signaling network and its role in cancer. Discov Med 12(66):419–432
42. Movafagh S, Crook S, Vo K (2015) Regulation of hypoxia-inducible factor-1a by reactive oxygen species: new developments in an old debate. J Cell Biochem 116(5):696–703. doi:10.1002/jcb.25074
43. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, Jain RK, Collen D, Keshert E (1998) Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394(6692):485–490. doi:10.1038/28867
44. Grimm S, Mvondo D, Grune T, Breusing N (2011) The outcome of 5-ALA-mediated photodynamic treatment in melanoma cells is influenced by vitamin C and heme oxygenase-1. BioFactors 37(1):17–24. doi:10.1002/biof.129
45. Ockaili R, Natarajan R, Salloum F, Fisher BJ, Jones D, Kukreja RC (2005) HIF-1 activation attenuates postischemic myocardial injury: role for heme oxygenase-1 in modulating microvascular chemokine generation. Am J Physiol Heart Circ Physiol 289(2):H542–H548
46. Wiedmann M, Feisthammel J, Bluthner T, Tannapfel A, Kamenz T, Kluge A, Mossner J, Caca K (2006) Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. Anticancer Drugs 17(7):783–795. doi:10.1097/01.cad.0000217433.48870.37
47. Fabregat A, Sidiropoulos K, Garapati P, Gillespie M, Hausmann K, Haw R, Jassal B, Jupe S, Korninger F, McKay S, Matthews L, May B, Milacic M, Rothfels K, Shamovsky V, Webber M, Weiser J, Williams M, Wu G, Stein L, Hermjakob H, D’Eustachio P (2016) The Reactome pathway knowledgebase. Nucleic Acids Res 44(D1):D481–D487. doi:10.1093/nar/gkv1351
48. Croft D, Mundo AF, Haw R, Milacic M, Weiser J, Wu G, Caudy M, Garapati P, Gillespie M, Kamdar MR, Jassal B, Jupe S, Matthews L, May B, Palatnik S, Rothfels K, Shamovsky V, Song H, Williams M, Birney E, Hermjakob H, Stein L, D’Eustachio P (2014) The Reactome pathway knowledgebase. Nucleic Acids Res 42 (Database issue):D472-477. doi:10.1093/nar/gkt1102
49. Zhang J, Zhang Y, Liu S, Zhang Q, Wang Y, Tong L, Chen X, Ji Y, Shang Q, Xu B, Chu M, Wei L (2013) Metadherin confers chemoresistance of cervical cancer cells by inducing autophagy and activating ERK/NF-kappaB pathway. Tumour Biol 34(4):2433–2440. doi:10.1007/s13277-013-0794-z
50. Wang HP, Hanlon JG, Rainbow AJ, Espiritu M, Singh G (2002) Up-regulation of Hsp27 plays a role in the resistance of human colon carcinoma HT29 cells to photooxidative stress. Photochem Photobiol 76(1):98–104
51. Wagner A, Wiedmann M, Tannapfel A, Mayr C, Kiesslich T, Wolkersdorfer GW, Berr F, Hauss J, Witzigmann H (2015) Neoadjuvant down-sizing of hilar cholangiocarcinoma with photodynamic therapy: long-term outcome of a phase II pilot study. Int J Mol Sci 16(11):26619–26628. doi:10.3390/ijms161125978
52. Zoepf T, Jakobs R, Arnold JC, Apel D, Riemann JF (2005) Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol 100(11):2426–2430. doi:10.1111/j.1572-0241.2005.00318.x
53. Buescher JM, Driggers EM (2016) Integration of omics: more than the sum of its parts. Cancer & metabolism 4:4. doi:10.1186/s40170-016-0143-y
54. Masoud GN, Li W (2015) HIF-1alpha pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B 5(5):378–389. doi:10.1016/j.apsb.2015.05.007
55. DiDonato JA, Mercurio F, Karin M (2012) NF-kappaB and the link between inflammation and cancer. Immunol Rev 246(1):379–400. doi:10.1111/j.1600-065X.2012.01099.x
56. Ji Z, Yang G, Shahzidi S, Tkacz-Stachowska K, Suo Z, Nesland JM, Peng Q (2006) Induction of hypoxia-inducible factor-1alpha overexpression by cobalt chloride enhances cellular resistance to photodynamic therapy. Cancer Lett 244(2):182–189. doi:10.1016/j.canlet.2005.12.010
57. Chen WH, Lecaros RL, Tseng YC, Huang L, Hsu YC (2015) Nanoparticle delivery of HIF1α siRNA combined with photodynamic therapy as a potential treatment strategy for head-and-neck cancer. Cancer Lett 359(1):65–74. doi:10.1016/j.canlet.2014.12.052
58. Li YJ, Zhou JH, Du XX, de Jia X, Wu CL, Huang P, Han Y, Sui H, Wei XL, Liu L, Yuan HH, Zhang TT, Zhang WJ, Xie R, Lang XH, Liu T, Jiang CL, Wang LY, Bai YX (2014) Dihydroartemisinin accentuates the anti-tumor effects of photodynamic therapy via inactivation of NF-kappaB in Eca109 and Ec9706 esophageal cancer cells. Cell Physiol Biochem 33(5):1527–1536. doi:10.1159/000358716
59. Coupienne I, Bontems S, Dewaele M, Rubio N, Habraken Y, Fulda S, Agostinis P, Piette J (2011) NF-kappaB inhibition improves the sensitivity of human glioblastoma cells to 5-aminolevulinic acid-based photodynamic therapy. Biochem Pharmacol 81(5):606–616. doi:10.1016/j.bcp.2010.12.015
60. Porta C, Riboldi E, Ippolito A, Sica A (2015) Molecular and epigenetic basis of macrophage polarized activation. Semin Immunol 27(4):237–248. doi:10.1016/j.smim.2015.10.003
61. Zhang Q, Li ZH, Li YY, Shi SJ, Zhou SW, Fu YY, Zhang Q, Yang X, Fu RQ, Lu LC (2015) Hypericin-photodynamic therapy induces human umbilical vein endothelial cell apoptosis. Sci Rep 5:18398. doi:10.1038/srep18398
62. Di Venosa G, Perotti C, Batlle A, Casas A (2015) The role of cytoskeleton and adhesion proteins in the resistance to photodynamic therapy. Possible therapeutic interventions. Photochem Photobiol Sci 14(8):1451–1464. doi:10.1039/c4pp00445k
63. Acedo P, Stockert JC, Canete M, Villanueva A (2014) Two combined photosensitizers: a goal for more effective photodynamic therapy of cancer. Cell Death Dis 5:e1122. doi:10.1038/cddis.2014.77
64. Galaz S, Espada J, Stockert JC, Pacheco M, Sanz-Rodriguez F, Arranz R, Rello S, Canete M, Villanueva A, Esteller M, Juarranz A (2005) Loss of E-cadherin mediated cell-cell adhesion as an early trigger of apoptosis induced by photodynamic treatment. J Cell Physiol 205(1):86–96. doi:10.1002/jcp.20374
65. Gendreau SB, Ventura R, Keast P, Laird AD, Yakes FM, Zhang W, Bentzien F, Cancilla B, Lutman J, Chu F, Jackman L, Shi Y, Yu P, Wang J, Aftab DT, Jaeger CT, Meyer SM, De Costa A, Engell K, Chen J, Martini JF, Joly AH (2007) Inhibition of the T790 M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647. Clin Cancer Res 13(12):3713–3723. doi:10.1158/1078-0432.ccr-06-2590
66. Martinez-Carpio PA, Trelles MA (2010) The role of epidermal growth factor receptor in photodynamic therapy: a review of the literature and proposal for future investigation. Lasers Med Sci 25(6):767–771. doi:10.1007/s10103-010-0790-0
67. Edmonds C, Hagan S, Gallagher-Colombo SM, Busch TM, Cengel KA (2012) Photodynamic therapy activated signaling from epidermal growth factor receptor and STAT3: Targeting survival pathways to increase PDT efficacy in ovarian and lung cancer. Cancer Biol Ther 13(14):1463–1470. doi:10.4161/cbt.22256
68. Kawczyk-Krupka A, Bugaj AM, Potempa M, Wasilewska K, Latos W, Sieron A (2015) Vascular-targeted photodynamic therapy in the treatment of neovascular age-related macular degeneration: clinical perspectives. Photodiagnosis Photodyn Ther 12(2):161–175. doi:10.1016/j.pdpdt.2015.03.007
69. Gallagher-Colombo SM, Miller J, Cengel KA, Putt ME, Vinogradov SA, Busch TM (2015) Erlotinib pretreatment improves photodynamic therapy of non-small cell lung carcinoma xenografts via multiple mechanisms. Cancer Res 75(15):3118–3126. doi:10.1158/0008-5472.can-14-3304
70. Yang PW, Hung MC, Hsieh CY, Tung EC, Wang YH, Tsai JC, Lee JM (2013) The effects of Photofrin-mediated photodynamic therapy on the modulation of EGFR in esophageal squamous cell carcinoma cells. Lasers Med Sci 28(2):605–614. doi:10.1007/s10103-012-1119-y
71. Tomanek L (2015) Proteomic responses to environmentally induced oxidative stress. J Exp Biol 218(Pt 12):1867–1879. doi:10.1242/jeb.116475
72. Ariza AC, Deen PM, Robben JH (2012) The succinate receptor as a novel therapeutic target for oxidative and metabolic stress-related conditions. Front Endocrinol 3:22. doi:10.3389/fendo.2012.00022
73. Mills E, O’Neill LA (2014) Succinate: a metabolic signal in inflammation. Trends Cell Biol 24(5):313–320. doi:10.1016/j.tcb.2013.11.008
74. Chouchani ET, Pell VR, Gaude E, Aksentijevic D, Sundier SY, Robb EL, Logan A, Nadtochiy SM, Ord EN, Smith AC, Eyassu F, Shirley R, Hu CH, Dare AJ, James AM, Rogatti S, Hartley RC, Eaton S, Costa AS, Brookes PS, Davidson SM, Duchen MR, Saeb-Parsy K, Shattock MJ, Robinson AJ, Work LM, Frezza C, Krieg T, Murphy MP (2014) Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature 515(7527):431–435. doi:10.1038/nature13909
75. Frank J, Lornejad-Schafer MR, Schoffl H, Flaccus A, Lambert C, Biesalski HK (2007) Inhibition of heme oxygenase-1 increases responsiveness of melanoma cells to ALA-based photodynamic therapy. Int J Oncol 31(6):1539–1545
76. Nowis D, Legat M, Grzela T, Niderla J, Wilczek E, Wilczynski GM, Glodkowska E, Mrowka P, Issat T, Dulak J, Jozkowicz A, Was H, Adamek M, Wrzosek A, Nazarewski S, Makowski M, Stoklosa T, Jakobisiak M, Golab J (2006) Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity. Oncogene 25(24):3365–3374. doi:10.1038/sj.onc.1209378
77. Kim J, Lim H, Kim S, Cho H, Kim Y, Li X, Choi H, Kim O (2016) Effects of HSP27 downregulation on PDT resistance through PDT-induced autophagy in head and neck cancer cells. Oncol Rep 35(4):2237–2245. doi:10.3892/or.2016.4597
78. Chatr-Aryamontri A, Breitkreutz BJ, Heinicke S, Boucher L, Winter A, Stark C, Nixon J, Ramage L, Kolas N, O’Donnell L, Reguly T, Breitkreutz A, Sellam A, Chen D, Chang C, Rust J, Livstone M, Oughtred R, Dolinski K, Tyers M (2013) The BioGRID interaction database: 2013 update. Nucleic Acids Res 41 (Database issue):D816–D823. doi:10.1093/nar/gks1158
79. Hornbeck PV, Kornhauser JM, Tkachev S, Zhang B, Skrzypek E, Murray B, Latham V, Sullivan M (2012) PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. Nucleic Acids Res 40 (Database issue):D261–D270. doi:10.1093/nar/gkr1122
80. Kelder T, van Iersel MP, Hanspers K, Kutmon M, Conklin BR, Evelo CT, Pico AR (2012) WikiPathways: building research communities on biological pathways. Nucleic Acids Res 40 (Database issue):D1301–D1307. doi:10.1093/nar/gkr1074